Tags

Type your tag names separated by a space and hit enter

Influenza virus neuraminidase inhibitors.
Lancet. 2000 Mar 04; 355(9206):827-35.Lct

Abstract

Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have been developed, and two (zanamivir and oseltamivir) have been approved for human use. Unlike amantadine and rimantadine that target the M2 protein of influenza A viruses, these drugs inhibit replication of both influenza A and B viruses. Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth. Early treatment with either drug reduces the severity and duration of influenza symptoms and associated complications. Both agents are effective for chemoprophylaxis. Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza.

Authors+Show Affiliations

Department of Internal Medicine, University of Virginia, School of Medicine, Charlottesville 22908, USA. lvg9b@virginia.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

10711940

Citation

Gubareva, L V., et al. "Influenza Virus Neuraminidase Inhibitors." Lancet (London, England), vol. 355, no. 9206, 2000, pp. 827-35.
Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827-35.
Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000). Influenza virus neuraminidase inhibitors. Lancet (London, England), 355(9206), 827-35.
Gubareva LV, Kaiser L, Hayden FG. Influenza Virus Neuraminidase Inhibitors. Lancet. 2000 Mar 4;355(9206):827-35. PubMed PMID: 10711940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza virus neuraminidase inhibitors. AU - Gubareva,L V, AU - Kaiser,L, AU - Hayden,F G, PY - 2000/3/11/pubmed PY - 2000/3/25/medline PY - 2000/3/11/entrez SP - 827 EP - 35 JF - Lancet (London, England) JO - Lancet VL - 355 IS - 9206 N2 - Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have been developed, and two (zanamivir and oseltamivir) have been approved for human use. Unlike amantadine and rimantadine that target the M2 protein of influenza A viruses, these drugs inhibit replication of both influenza A and B viruses. Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth. Early treatment with either drug reduces the severity and duration of influenza symptoms and associated complications. Both agents are effective for chemoprophylaxis. Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/10711940/Influenza_virus_neuraminidase_inhibitors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(99)11433-8 DB - PRIME DP - Unbound Medicine ER -